Clinical trials: Takayasu Arteritis (TAK)
Takayasu Arteritis (TAK), Takayasu's Arteritis
Global Initiative on Takayasu Arteritis (GITA)
Takayasu's Arteritis Global Registry aims to bring a large group of patients from different parts of the world to analyse and compare the patients' demographic, clinical, laboratory, radiological and prognostic features with…
- Trial name
- GITA (NCT07558382)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Marmara University
Aortitis, Cutaneous Vasculitis
VCRC Tissue Repository
The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies.
- Conditions
- Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis
- Trial name
- NCT02967068
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Takayasu Arteritis
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing Takayasu Arteritis (TAK).
- Trial name
- NCT04882072
- Testing
- Ustekinumab, Glucorticoid Taper Regimen
- Where
- 27 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Janssen Pharmaceutical K.K.
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis
One-Time DNA Study for Vasculitis
The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis
- Trial name
- NCT01241305
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Takayasu Arteritis (TAK)
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.
- Trial name
- SELECT-TAK (NCT04161898)
- Testing
- Upadacitinib, Prednisolone
- Where
- 48 sites in Argentina, Brazil and 4 more
- Volunteers
- 56 people
- Sponsor
- AbbVie